Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10911846 | Lung Cancer | 2005 | 4 Pages |
Abstract
Gefitinib (Iressa, ZD1839) is an orally active inhibitor selective for the epidermal growth factor receptor tyrosine kinase and has shown promise in the treatment of non-small cell lung cancer (NSCLC). There has been no report to date of the effect of gefitinib treatment in patients with small-cell lung cancer (SCLC). Here we report a case of metastatic SCLC that was successfully treated with gefitinib. This case is the first reported of objective clinical response after gefitinib treatment in a patient with SCLC. Our report suggests that treatment with gefitinib is a novel option for a subset of patients with SCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jun Araki, Isamu Okamoto, Ryuichiro Suto, Yasuko Ichikawa, Ji-ichiro Sasaki,